State-of-the-art gene therapy in epilepsy
Open Access
- 7 February 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 38 (2) , 128-134
Abstract
Purpose of review: Gene therapy in epilepsy has undergone a rapid expansion in recent years. This has largely been driven by both advances in our understanding of epilepsy genetics and mechanisms, and also significant advances in gene therapy tools, in particular safe and effective viral vectors. Epilepsy remains an ideal target disease for gene therapy and this review highlights recent developments in this area. Recent findings: There have been continued advances in the development of antisense oligonucleotide therapies to knock down genes in the treatment of monogenic epilepsies with some now entering clinical trial. However, the greatest recent advances have been in vector gene therapy, which offers a more permanent solution by delivering therapeutic genes directly to the brain as a one-off therapy. In particular, there has been a growth in methods that target focal epilepsy. Such promising approaches close to or in clinical trial include expressing NPY and its Y2 receptor, knocking-down GluK5, a kainate receptor subunit, and the over-expression of Kv1.1, an endogenous potassium channel. In the future, it is likely that we will take advantage of approaches of regulating more precisely network excitability by using methods such as optogenetics, designer receptors exclusively activated by designer drugs (DREADDs), ‘inhibitory’ glutamate receptors activated by excessive glutamate spill-over, and activity-dependent promoters, which target gene expression to the ‘hyperactive’ neurons. Summary: Gene therapies offer a novel approach to the treatment of not just genetic epilepsies but any form of epilepsy and may in the future offer an alternative to drug and surgical therapies, allowing more precise, permanent and targeted treatment with fewer adverse effects.Keywords
This publication has 49 references indexed in Scilit:
- Allele‐Specific Editing of a Dominant SCN8A Epilepsy Variant Protects against Seizures and Lethality in a Murine ModelAnnals of Neurology, 2024
- Long‐Term Downregulation of the Sodium Channel Gene Scn8a Is Therapeutic in Mouse Models of SCN8A EpilepsyAnnals of Neurology, 2024
- Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndromeJournal of Molecular Medicine, 2023
- GluK2 Is a Target for Gene Therapy in Drug‐Resistant Temporal Lobe EpilepsyAnnals of Neurology, 2023
- Disease Modification by Combinatorial Single Vector Gene Therapy: A Preclinical Translational Study in EpilepsyMolecular Therapy - Methods & Clinical Development, 2019
- Therapeutic AAV Gene Transfer to the Nervous System: A Clinical RealityNeuron, 2019
- Viral vectors for therapy of neurologic diseasesNeuropharmacology, 2017
- Adeno associated viral vector-mediated expression of somatostatin in rat hippocampus suppresses seizure developmentNeuroscience Letters, 2012
- In vitro effects of neuropeptide Y in rat neocortical and hippocampal tissueNeuroscience Letters, 2011
- Gene therapy for neurological disordersTrends in Genetics, 1994